Omnio's €2.9M plasminogen bet on diabetic foot ulcers: credible mechanism, unproven market
Omnio AB closed an oversubscribed €2.9 million round in Umeå on 1 October 2026, funding a master cell bank, a GMP batch and the toxicology package for a Phase I/IIa study in diabetic foot ulcers targeted for 2027. The plasminogen mechanism has independent support in human wound fluid.